Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEPTUNE
ISRCTN55804223Phase 2Terminated
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
- Start
- Oct 2020
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Alpha Emitters → Radiopharmaceuticals, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2 trial of avelumab and radium-223 dichloride, sponsored by Sheffield Teaching Hospitals NHS Foundation Trust. Started Oct 2020; status: terminated.
02
Drugs
avelumabradium-223 dichloride
Beyond the preview
Go deeper on ISRCTN55804223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN55804223.